Tarsus Pharma Files Proxy Statement for 2025 Shareholder Meeting
Ticker: TARS · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1819790
| Field | Detail |
|---|---|
| Company | Tarsus Pharmaceuticals, Inc. (TARS) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Tarsus Pharma proxy filed. Vote on directors & pay.
AI Summary
Tarsus Pharmaceuticals, Inc. filed its definitive proxy statement (DEF 14A) on April 28, 2025, for its annual meeting on June 12, 2025. The filing provides details regarding the company's governance and matters to be voted on by shareholders, including the election of directors and executive compensation.
Why It Matters
This filing is crucial for shareholders as it outlines the company's leadership, executive pay, and key proposals that will be voted on, directly impacting corporate governance and future strategy.
Risk Assessment
Risk Level: low — This is a routine proxy filing, providing information to shareholders about upcoming meetings and corporate governance, with no immediate material financial events disclosed.
Key Numbers
- 20250428 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 20250612 — Meeting Date (Date of the shareholder meeting for which this proxy statement is issued.)
Key Players & Entities
- Tarsus Pharmaceuticals, Inc. (company) — Registrant
- 0001819790-25-000070 (filing_id) — Accession Number
- 20250428 (date) — Filing Date
- 20250612 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used by companies to solicit proxy votes from shareholders for their annual or special meetings. It contains detailed information about the matters to be voted on, such as director elections, executive compensation, and other corporate proposals.
Who is the filer of this document?
The filer of this document is Tarsus Pharmaceuticals, Inc., as indicated by the 'Registrant' designation and the company name specified in the filing.
When was this proxy statement filed?
This proxy statement was filed on April 28, 2025.
When is the shareholder meeting scheduled?
The shareholder meeting for which this proxy statement is issued is scheduled for June 12, 2025.
What is Tarsus Pharmaceuticals, Inc.'s primary business?
Tarsus Pharmaceuticals, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Tarsus Pharmaceuticals, Inc. (TARS).